questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
bêta-Lactames
Céphalosporines
Céfamycines
Céfoxitine
Céfoxitine : Questions médicales fréquentes
Diagnostic
5
Infections bactériennes
Diagnostic médical
Tests de laboratoire
Culture bactérienne
Infections résistantes
Antibiotiques
Symptômes cliniques
Infections
Sensibilité bactérienne
Antibiotiques
Symptômes
5
Pneumonie
Infections urinaires
Infections abdominales
Symptômes
Infections cutanées
Antibiotiques
Consultation médicale
Symptômes
Infections urinaires
Symptômes
Prévention
5
Prévention des infections
Hygiène
Hygiène
Prévention des infections
Antibiotiques préventifs
Prévention
Résistance aux antibiotiques
Utilisation des antibiotiques
Traitements
5
Administration de médicaments
Injections
Effets secondaires
Antibiotiques
Interactions médicamenteuses
Antibiotiques
Durée du traitement
Infections
Complications
5
Complications
Réactions allergiques
Réaction allergique
Consultation médicale
Infections secondaires
Complications
Complications graves
Urgence médicale
Troubles gastro-intestinaux
Effets secondaires
Facteurs de risque
5
Facteurs de risque
Infections
Personnes âgées
Immunodépression
Infections nosocomiales
Hospitalisation
Immunodépression
Infections
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Céfoxitine : Questions médicales les plus fréquentes",
"headline": "Céfoxitine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Céfoxitine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-18",
"dateModified": "2026-03-10",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Céfoxitine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Céfamycines",
"url": "https://questionsmedicales.fr/mesh/D002513",
"about": {
"@type": "MedicalCondition",
"name": "Céfamycines",
"code": {
"@type": "MedicalCode",
"code": "D002513",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.300.249.250"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Céfoxitine",
"alternateName": "Cefoxitin",
"code": {
"@type": "MedicalCode",
"code": "D002440",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Emmanuel Novy",
"url": "https://questionsmedicales.fr/author/Emmanuel%20Novy",
"affiliation": {
"@type": "Organization",
"name": "Department of Anaesthesiology Critical Care and perioperative medicine, Nancy University Hospital, University of Lorraine, Vandoeuvre-Lès-Nancy, 54500, France; UR 7300, SIMPA, Université de Lorraine, 54000, Nancy, France; UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, 4029, Australia. Electronic address: e.novy@chru-nancy.fr."
}
},
{
"@type": "Person",
"name": "Thibaut Belveyre",
"url": "https://questionsmedicales.fr/author/Thibaut%20Belveyre",
"affiliation": {
"@type": "Organization",
"name": "Department of Anaesthesiology Critical Care and perioperative medicine, Nancy University Hospital, University of Lorraine, Vandoeuvre-Lès-Nancy, 54500, France."
}
},
{
"@type": "Person",
"name": "Julien Scala-Bertola",
"url": "https://questionsmedicales.fr/author/Julien%20Scala-Bertola",
"affiliation": {
"@type": "Organization",
"name": "Department of Clinical Pharmacology and Toxicology, Nancy University Hospital, Vandoeuvre-Lès-Nancy, 54500, France; CNRS, IMoPA, Université de Lorraine, 54000, Nancy, France."
}
},
{
"@type": "Person",
"name": "Zaccaria Ricci",
"url": "https://questionsmedicales.fr/author/Zaccaria%20Ricci",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Cardiology and Cardiac Surgery, Pediatric Cardiac Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy."
}
},
{
"@type": "Person",
"name": "Simona Benegni",
"url": "https://questionsmedicales.fr/author/Simona%20Benegni",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Cardiology and Cardiac Surgery, Pediatric Cardiac Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Remarkable antibiofilm activity of ciprofloxacin, cefoxitin, and tobramycin, by themselves or in combination, against enteroaggregative Escherichia coli in vitro.",
"datePublished": "2023-08-02",
"url": "https://questionsmedicales.fr/article/37657231",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.diagmicrobio.2023.116048"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cefoxitin versus carbapenems as definitive treatment for extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteremia in intensive care unit: a propensity-matched retrospective analysis.",
"datePublished": "2023-11-01",
"url": "https://questionsmedicales.fr/article/37915017",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13054-023-04712-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Unraveling the mechanisms of Cefoxitin resistance in methicillin-resistant",
"datePublished": "2023-10-09",
"url": "https://questionsmedicales.fr/article/37811561",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/07391102.2023.2262591"
}
},
{
"@type": "ScholarlyArticle",
"name": "Are Antibiotics of Value for a Whipple Procedure?",
"datePublished": "2024-05-23",
"url": "https://questionsmedicales.fr/article/39089788",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.yasu.2024.04.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "",
"datePublished": "2023-08-23",
"url": "https://questionsmedicales.fr/article/37610203",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1128/aac.00258-23"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "bêta-Lactames",
"item": "https://questionsmedicales.fr/mesh/D047090"
},
{
"@type": "ListItem",
"position": 6,
"name": "Céphalosporines",
"item": "https://questionsmedicales.fr/mesh/D002511"
},
{
"@type": "ListItem",
"position": 7,
"name": "Céfamycines",
"item": "https://questionsmedicales.fr/mesh/D002513"
},
{
"@type": "ListItem",
"position": 8,
"name": "Céfoxitine",
"item": "https://questionsmedicales.fr/mesh/D002440"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Céfoxitine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Céfoxitine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Céfoxitine",
"description": "Comment diagnostiquer une infection nécessitant la céfoxitine ?\nQuels tests sont utilisés pour confirmer une infection ?\nQuand envisager l'utilisation de céfoxitine ?\nQuels signes cliniques indiquent une infection ?\nLa céfoxitine est-elle efficace contre toutes les bactéries ?",
"url": "https://questionsmedicales.fr/mesh/D002440#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Céfoxitine",
"description": "Quels symptômes traitent la céfoxitine ?\nQuels sont les signes d'une infection abdominale ?\nLa céfoxitine traite-t-elle les infections cutanées ?\nQuels symptômes d'une infection nécessitent une consultation ?\nLes infections urinaires ont-elles des symptômes spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D002440#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Céfoxitine",
"description": "Comment prévenir les infections traitées par céfoxitine ?\nLes vaccinations aident-elles à prévenir les infections ?\nQuelles pratiques d'hygiène sont recommandées ?\nLes antibiotiques préventifs sont-ils efficaces ?\nComment éviter la résistance aux antibiotiques ?",
"url": "https://questionsmedicales.fr/mesh/D002440#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Céfoxitine",
"description": "Comment la céfoxitine est-elle administrée ?\nQuelle est la posologie standard de céfoxitine ?\nQuels sont les effets secondaires de la céfoxitine ?\nLa céfoxitine peut-elle interagir avec d'autres médicaments ?\nCombien de temps dure un traitement avec céfoxitine ?",
"url": "https://questionsmedicales.fr/mesh/D002440#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Céfoxitine",
"description": "Quelles complications peuvent survenir avec la céfoxitine ?\nComment gérer une réaction allergique à la céfoxitine ?\nLes infections secondaires sont-elles fréquentes ?\nQuels signes indiquent une complication grave ?\nLa céfoxitine peut-elle causer des troubles gastro-intestinaux ?",
"url": "https://questionsmedicales.fr/mesh/D002440#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Céfoxitine",
"description": "Quels sont les facteurs de risque d'infection ?\nLes personnes âgées sont-elles plus à risque ?\nLe diabète influence-t-il le risque d'infection ?\nLes patients hospitalisés sont-ils à risque accru ?\nComment l'immunodépression affecte-t-elle le risque d'infection ?",
"url": "https://questionsmedicales.fr/mesh/D002440#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection nécessitant la céfoxitine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur des symptômes cliniques et des cultures bactériennes."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer une infection ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de culture, des tests de sensibilité et des analyses sanguines sont utilisés."
}
},
{
"@type": "Question",
"name": "Quand envisager l'utilisation de céfoxitine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est envisagée pour des infections graves ou résistantes aux autres antibiotiques."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une infection ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, douleur, rougeur et gonflement peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "La céfoxitine est-elle efficace contre toutes les bactéries ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, son efficacité dépend du type de bactérie et de sa sensibilité aux antibiotiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes traitent la céfoxitine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle traite des infections comme la pneumonie, les infections abdominales et urinaires."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une infection abdominale ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Douleurs abdominales, fièvre, nausées et vomissements peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "La céfoxitine traite-t-elle les infections cutanées ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est utilisée pour traiter certaines infections cutanées bactériennes."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une infection nécessitent une consultation ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre élevée, douleur intense ou symptômes persistants nécessitent une consultation."
}
},
{
"@type": "Question",
"name": "Les infections urinaires ont-elles des symptômes spécifiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, brûlures à la miction, besoin fréquent d'uriner et douleurs pelviennes."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections traitées par céfoxitine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir une bonne hygiène, se faire vacciner et éviter les contacts avec des malades."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles à prévenir les infections ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines vaccinations peuvent réduire le risque d'infections bactériennes."
}
},
{
"@type": "Question",
"name": "Quelles pratiques d'hygiène sont recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Se laver les mains régulièrement et désinfecter les surfaces fréquemment touchées."
}
},
{
"@type": "Question",
"name": "Les antibiotiques préventifs sont-ils efficaces ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être efficaces dans certains cas, mais leur utilisation doit être prudente."
}
},
{
"@type": "Question",
"name": "Comment éviter la résistance aux antibiotiques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser les antibiotiques uniquement lorsque nécessaire et suivre les prescriptions médicales."
}
},
{
"@type": "Question",
"name": "Comment la céfoxitine est-elle administrée ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est généralement administrée par injection intraveineuse ou intramusculaire."
}
},
{
"@type": "Question",
"name": "Quelle est la posologie standard de céfoxitine ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie varie selon l'infection, mais elle est souvent de 1 à 2 g toutes les 6 à 8 heures."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires de la céfoxitine ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des nausées, des éruptions cutanées et des diarrhées."
}
},
{
"@type": "Question",
"name": "La céfoxitine peut-elle interagir avec d'autres médicaments ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut interagir avec d'autres antibiotiques et anticoagulants, nécessitant prudence."
}
},
{
"@type": "Question",
"name": "Combien de temps dure un traitement avec céfoxitine ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée du traitement dépend de l'infection, généralement de 5 à 14 jours."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la céfoxitine ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques, des infections secondaires ou des troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment gérer une réaction allergique à la céfoxitine ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cesser immédiatement le traitement et consulter un médecin pour évaluation."
}
},
{
"@type": "Question",
"name": "Les infections secondaires sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent survenir, surtout si le traitement est prolongé ou inapproprié."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des difficultés respiratoires ou un gonflement du visage nécessitent une urgence."
}
},
{
"@type": "Question",
"name": "La céfoxitine peut-elle causer des troubles gastro-intestinaux ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des nausées, vomissements ou diarrhées peuvent survenir comme effets secondaires."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'infection ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Âge avancé, immunodépression, diabète et hospitalisation augmentent le risque d'infection."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles ont un système immunitaire affaibli, les rendant plus vulnérables aux infections."
}
},
{
"@type": "Question",
"name": "Le diabète influence-t-il le risque d'infection ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut altérer la réponse immunitaire et augmenter le risque d'infections."
}
},
{
"@type": "Question",
"name": "Les patients hospitalisés sont-ils à risque accru ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hospitalisation expose à des bactéries résistantes et à des infections nosocomiales."
}
},
{
"@type": "Question",
"name": "Comment l'immunodépression affecte-t-elle le risque d'infection ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle réduit la capacité du corps à combattre les infections, augmentant le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 10/03/2026
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Anaesthesiology Critical Care and perioperative medicine, Nancy University Hospital, University of Lorraine, Vandoeuvre-Lès-Nancy, 54500, France; UR 7300, SIMPA, Université de Lorraine, 54000, Nancy, France; UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, 4029, Australia. Electronic address: e.novy@chru-nancy.fr.
Publications dans "Céfoxitine" :
3 publications dans cette catégorie
Affiliations :
Department of Anaesthesiology Critical Care and perioperative medicine, Nancy University Hospital, University of Lorraine, Vandoeuvre-Lès-Nancy, 54500, France.
Publications dans "Céfoxitine" :
3 publications dans cette catégorie
Affiliations :
Department of Clinical Pharmacology and Toxicology, Nancy University Hospital, Vandoeuvre-Lès-Nancy, 54500, France; CNRS, IMoPA, Université de Lorraine, 54000, Nancy, France.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
From the Department of Cardiology and Cardiac Surgery, Pediatric Cardiac Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
From the Department of Cardiology and Cardiac Surgery, Pediatric Cardiac Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
From the Department of Cardiology and Cardiac Surgery, Pediatric Cardiac Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
From the Department of Cardiology and Cardiac Surgery, Pediatric Cardiac Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
From the Department of Cardiology and Cardiac Surgery, Pediatric Cardiac Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
From the Department of Cardiology and Cardiac Surgery, Pediatric Cardiac Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
Faculty of Public Health, Kasetsart University Chalermphrakiat Sakon Nakhon Province Campus, Sakon Nakhon, Thailand.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
Faculty of Public Health, Kasetsart University Chalermphrakiat Sakon Nakhon Province Campus, Sakon Nakhon, Thailand.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
Faculty of Public Health, Kasetsart University Chalermphrakiat Sakon Nakhon Province Campus, Sakon Nakhon, Thailand.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
Faculty of Public Health, Kasetsart University Chalermphrakiat Sakon Nakhon Province Campus, Sakon Nakhon, Thailand.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
Faculty of Science and Engineering, Kasetsart University Chalermphrakiat Sakon Nakhon Province Campus, Sakon Nakhon, Thailand.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
Faculty of Public Health, Kasetsart University Chalermphrakiat Sakon Nakhon Province Campus, Sakon Nakhon, Thailand.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
Memorial Sloan Kettering Cancer Center, New York, New York.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
American College of Surgeons, Chicago, Illinois.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
University of Texas Southwestern Medical Center, Dallas.
Publications dans "Céfoxitine" :
2 publications dans cette catégorie
Affiliations :
American College of Surgeons, Chicago, Illinois.
Rutgers Cancer Institute of New Jersey, New Brunswick.
Publications dans "Céfoxitine" :
Enteroaggregative Escherichia coli (EAEC), a biofilm forming pathogen, causes acute and persistent diarrhea worldwide, requiring antimicrobial therapy in severe or persistent cases. To determine the s...
Despite cefoxitin's in vitro resistance to hydrolysis by extended-spectrum beta-lactamases (ESBL), treatment of ESBL-producing Klebsiella pneumoniae (KP) infections with cefoxitin remains controversia...
This retrospective study included all patients with monomicrobial bacteremia hospitalized in intensive care unit between January 2013 and January 2023 at the University Hospital of Guadeloupe. The pri...
A total of 110 patients with bloodstream infections were enrolled. Sixty-three patients (57%) received definitive antibiotic therapy with cefoxitin, while forty-seven (43%) were treated with carbapene...
Our results suggest that cefoxitin as definitive antibiotic therapy could be a therapeutic option for some ESBL-KP bacteremia, sparing carbapenems and reducing the selection of carbapenem-resistant Ps...
Pancreatoduodenectomy is a complex surgical procedure with a high rate of morbidity, of which surgical-site infections (SSIs) make a large portion. Reduction of SSI rates is critical to decrease hospi...
This study compared the efficacy of flomoxef with other β-lactam antibiotics against extended-spectrum β-lactamases (ESBL)-producing bacteria of clinical relevance. First, the prevalence and β-lactama...
The purpose of this research is to evaluate the resistance profile of uropathogenic staphylococci bacteria in Casablanca, Morocco....
In this retrospective cross-sectional research carried out from January 2017 to December 2020, isolation and identification were carried out according to the usual techniques in medical microbiology. ...
The prevalence of urinary tract infections (UTIs) was 18% (772/4374). UTIs were more common in females (n = 483, 63%) than males (n = 289, 37%). Among the Gram-positive bacteria isolated (198, 25.65%)...
The prevalence and antibacterial resistance patterns of uropathogenic staphylococci in this study, with a high percentage of methicillin resistance, require careful consideration of antimicrobial ther...
Mycobacterium abscessus (MABS) is the most pathogenic and drug-resistant rapidly growing mycobacteria. However, studies on MABS epidemiology, especially those focusing on subspecies level, are scarce....
To establish the association between bactibilia and postoperative complications when stratified by perioperative antibiotic prophylaxis....
Patients undergoing pancreatoduodenectomy experience high rates of surgical site infection (SSI) and clinically relevant postoperative pancreatic fistula (CR-POPF). Contaminated bile is known to be as...
Intraoperative bile cultures (IOBCs) were collected as an adjunct to a randomized phase 3 clinical trial comparing piperacillin-tazobactam with cefoxitin as perioperative prophylaxis in patients under...
Of 778 participants in the clinical trial, IOBC were available for 247 participants. Overall, 68 (27.5%) grew no organisms, 37 (15.0%) grew 1 organism, and 142 (57.5%) were polymicrobial. Organisms re...
Previously observed reductions in SSI and CR-POPF in patients that received piperacillin-tazobactam antibiotic prophylaxis are potentially mediated by biliary pathogens that are cefoxitin resistant, s...
Lower respiratory tract infections (LRTIs) caused by drug-resistant pathogenic bacteria is a major problem in developing countries including Ethiopia. Therefore, this study aimed to determine the path...
This institutional-based cross-sectional study was conducted from February 01 to March 15, 2020. Socio-demographic data were collected by using a structured questionnaire. A total of 254 sputum specim...
In this study, the overall sputum culture positivity rate was 145/254 (57.1%). Gram-negative bacteria 111 (64.9%) were predominant compared to Gram-positive bacteria 60 (35.1%). Of the 145 culture-pos...
This study revealed a higher burden of Gram-negative and Gram-positive pathogenic bacterial agents, which is responsible for LRTs. Therefore, routine sputum culture identification and antibiotic susce...
This study describes the population pharmacokinetics of cefoxitin in obese patients undergoing elective bariatric surgery and evaluates different dosing regimens for achievement of pre-defined target ...
Serial blood samples were collected during surgery with relevant clinical data. Total serum cefoxitin concentrations were measured by chromatographic assay and analysed using a population PK approach ...
A total of 123 obese patients (median BMI 44.3 kg/m...
Intermittent dosing regimens resulted in optimal FTAs against susceptible MIC distributions of S. aureus and E. coli when simulating with 50% cefoxitin protein binding. Continuous infusion of cefoxiti...
Registration on ClinicalTrials.gov, NCT03306290....